Overview
A drug recall is a voluntary or FDA-requested action taken by a manufacturer to remove a medication from the market, or to correct it, because it does not meet safety, quality, or labeling standards. Recalls are one of the primary tools the FDA and drug manufacturers use to protect patients once a problem is discovered after a product has already reached pharmacies and consumers.
This specific drug recall involving ENALAPRIL MALEATE is classified as Class II, and was reported on May 13, 2026 by JB Chemicals and Pharmaceuticals Ltd.
The sections below explain, in plain language, what is known about this drug recall, who it may affect, and what steps patients and caregivers can reasonably take. This article is an independent summary written for educational purposes and is not a substitute for the official FDA notice linked at the end of this page.
What Happened
JB Chemicals and Pharmaceuticals Ltd initiated action on ENALAPRIL MALEATE on May 13, 2026 after identifying a product quality or potency issue. The action affects specific lots or units of this medication rather than every unit ever produced, so not every package on the market is necessarily involved.
The action is described in FDA records as voluntary: firm initiated, and its current status in FDA records is listed as "Ongoing". Recall status can change as the firm works through correction or removal, so the most current information is always the official FDA recall record linked below.
Affected Products
The product identified in this notice is ENALAPRIL MALEATE, manufactured or distributed by JB Chemicals and Pharmaceuticals Ltd.
FDA records describe the affected product as: Enalapril Maleate Tablets, USP, 20 mg, 1,000-count bottle, Rx only, Manufactured by: Unique Pharmaceutical Laboratories (A Div. of J.B. Chemicals & Pharmaceuticals Ltd.), Mumbai 400 030, India, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 64980-688-10.
Identifying details on record include specific lot numbers, batch codes, or serial numbers documented as Lot #: GEH25023, Expires: 6/30/2027; a reported quantity of 675 bottles; distribution reported as Nationwide in the USA; origin or reporting location of Mumbai, India. If you have this product, compare it against these identifiers before assuming it is affected — many recalls apply to only a subset of lots, not an entire product line.
Reason
Based on FDA records, this notice was driven by a product quality or potency issue. In general terms, this kind of issue is flagged because it has the potential to affect how safely or effectively the product performs once it reaches a patient.
According to the FDA's Drug Enforcement Report database, the stated reason was: "Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test"